Sai Parenterals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Transformational year, investment phase continues: Consolidated revenue grew 133% to ₹381 crore driven by the Noumed acquisition and CDMO exports, but FY27 remains an investment year with no incremental revenue from the ₹440 crore capex program.
• Noumed rewrites the strategy: The acquisition added 451 IP dossiers and a turnkey Australian platform, shifting Sai from a manufacturer to a global IP-led business with accelerated 6-9 month product launch timelines.
• FY27 guidance embeds a deliberate ramp: The ₹750 crore revenue target and 17% EBITDA margin target reflect a back-half-weighted year, with backward integration of Noumed's manufacturing starting only in Q4.
• Peak debt, peak investment, then payoff: FY27 is the peak debt year at ₹319 crores; debt is expected to decline from FY28 as capex completes and assets begin contributing to earnings and cash flows.
• What to watch next quarter: Any revision to the ₹750 crore revenue target, progress on Noumed's Adelaide plant commissioning, and the pace of dossier commercialization from the 67 under development.

The Noumed Acquisition: Strategy & Integration

• Platform transformation: The acquisition, completed November 2025, added 451 IP dossiers and last-mile commercialization capability in Australia, cutting Sai's product launch timelines from 18-24 months to 6-9 months.
• Turnkey moat: Noumed is the only organization in Australia providing a full turnkey solution (owning IP, manufacturing, releasing, distributing) for multinational customers, with two top-20 ASX-listed customers covering 2,100 of 5,500 Australian pharmacies.
• Vertical integration underway: Sai's India facility has already begun supplying Noumed with IP dossiers for the Australian market, and the plan is to progressively shift Noumed's outsourced CMO production to Sai's own facilities starting Q4 FY27, capturing the margin currently lost to third-party manufacturers.
• Adelaide facility on track: The AUD 5.3 crore expansion project has seen AUD 4 crore invested to date; TGA commissioning begins October/November 2026 with packing of solid dosage forms, moving to liquids manufacturing in Q1 of the Australian calendar year, and a TGA license expected no later than March 31, 2027.

Mark Thulborne: "This is the only organization in Australia that does the full turnkey solution for its multinational customers at this point in time."

FY27 Guidance & Revenue Build

• ₹750 crore target with seasonal skew: Management guided ₹750 crore consolidated revenue for FY27, with the typical 40:60 H1:H2 split implying a materially stronger second half as Noumed integration and dossier commercialization accelerate.
• Conservatism questioned: Per an analyst's math, annualizing Q4 FY26 revenue of ₹198 crore would imply ~₹800 crore; management pointed to seasonality (Q3 and Q4 are heavier than Q1 and Q2) and said they would review the number next quarter and may revise upward.
• Revenue drivers identified: Execution of existing long-term contracts, commercialization of new dossiers (67 under development for FY27 and FY28), increasing Noumed contribution, and continued CDMO export momentum.
• No FY27 capex contribution: None of the ongoing ₹440 crore capex program is expected to contribute to FY27 financial performance, as most facilities will be commissioned toward the end of the year; the full impact arrives in FY28.

Anil Kumar Karusala: "We have right now target, given a guidance revenue for only this year. Once this is completed, basing on our molecules filing and the approvals, we would be presenting the guidance for the next year at the end of this financial year."

Margin Trajectory & Backward Integration

• Q4 base and FY27 target: Consolidated Q4 FY26 EBITDA margin was approximately 14.6%; management targets 17% for FY27, with the improvement driven by shifting Noumed's manufacturing from external CMOs to Sai's own facilities.
• The margin mechanics: Noumed currently sources products from various Indian CMOs; as these products move to Sai's manufacturing, the margin currently captured by third parties flows into Noumed and consolidates at the group level, with own-manufacturing at the Adelaide plant starting in Q4 FY27 and full integration by FY28.
• Tax tailwind: The company moved from the old tax regime (25%) to the new regime (22%), and created a deferred tax asset that resulted in a negative tax line for the quarter, both of which support reported profitability.

Capex, Debt & The Path to Monetization

• ₹440 crore program fully mapped: ₹111 crore for capacity expansion and EU-GMP upgrades in India (IPO-funded), ₹18 crore for an R&D center in India (IPO-funded), and AUD 5.3 crore (₹311 crore) for the Adelaide manufacturing facility (partly funded by an AUD 2 crore Australian government grant, with the balance from debt and internal accruals).
• FY27 as peak debt year: Total debt stood at ₹319 crore as of March 2026; management expects debt to peak in FY27 as the capex programs complete, then decline from FY28 as assets begin contributing to earnings and cash flows.
• Working capital improving: The shift toward CDMO business, with its long-term contracts and shorter receivable cycles, is expected to improve the working capital cycle over the next few quarters; approximately 25% of additional revenues will be required as working capital, funded through internal accruals and some debt.
• FY28 as the payoff year: Management explicitly frames FY28 as the year when the majority of the capex program becomes operational, with the new Australian facility, expanded Indian capacities, EU-GMP compliant infrastructure, and the R&D center all contributing to revenue, margin expansion, and profitability.

Anil Kumar Karusala: "We will move from a phase of building assets to a phase of monetizing them."

Dossier Portfolio & Commercialization Pipeline

• 88 approvals in FY26: Dossiers were approved across regulated and emerging markets during the year, with Noumed adding 5 dossiers in Australia in Q4 alone.
• 67 dossiers in the pipeline: These are under development and expected to be commercialized during FY27 and FY28, forming the product-launch engine that underpins the revenue growth story.
• IP-led speed advantage: The Noumed dossier portfolio accelerates launch timelines from the industry-typical 18-24 months to 6-9 months, a structural advantage that management cites as providing high certainty and sustainability to revenue and profit growth over the next three to four years.

Standalone Performance & CDMO Momentum

• Standalone revenue grew 30% to ₹162 crore, driven by CDMO business expansion, export growth, and strengthening customer relationships across regulated and emerging markets.
• Standalone profitability: EBITDA was 21% of revenues at ₹33 crore, and PAT grew 64% over FY25 to ₹17 crore.
• CDMO working capital benefit: The transition toward CDMO business improves working capital efficiency due to long-term contracts and shorter receivable cycles, an effect expected to become more pronounced as CDMO exports increase their contribution.

Guidance & Commitments

Key Metrics